Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Sino Biopharmaceutical Dividend Announcement
• Sino Biopharmaceutical announced a semi annually dividend of $0.00 per ordinary share which will be made payable on 2024-10-04. Ex dividend date: 2024-09-10
• Sino Biopharmaceutical annual dividend for 2024 was $0.01
• Sino Biopharmaceutical annual dividend for 2023 was $0.01
• Sino Biopharmaceutical's trailing twelve-month (TTM) dividend yield is 2.68%
• Sino Biopharmaceutical's payout ratio for the trailing twelve months (TTM) is 17.11%
• Sino Biopharmaceutical's dividend growth over the last five years (2018-2023) was -1.82% year
• Sino Biopharmaceutical's dividend growth over the last ten years (2013-2023) was 21.15% year
Sino Biopharmaceutical Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-09-10 | $0.00 | semi annually | 2024-10-04 |
2024-06-11 | $0.00 | semi annually | 2024-07-05 |
2023-10-04 | $0.00 | semi annually | 2023-10-27 |
2023-06-20 | $0.01 | semi annually | 2023-07-17 |
2022-09-06 | $0.01 | semi annually | 2022-09-28 |
2022-06-15 | $0.01 | semi annually | 2022-07-12 |
2021-09-13 | $0.00 | semi annually | 2021-10-04 |
2021-06-18 | $0.01 | semi annually | 2021-07-12 |
2020-12-11 | $0.00 | semi annually | 2020-12-31 |
2020-09-14 | $0.00 | semi annually | 2020-09-30 |
2020-06-12 | $0.01 | semi annually | 2020-07-06 |
2019-12-10 | $0.00 | semi annually | 2019-12-27 |
2019-09-12 | $0.00 | semi annually | 2019-09-30 |
2019-06-14 | $0.01 | semi annually | 2019-07-05 |
2018-12-06 | $0.00 | semi annually | 2018-09-28 |
2018-06-04 | $0.01 | semi annually | 2018-06-25 |
2017-11-28 | $0.00 | semi annually | 2017-12-15 |
2017-07-06 | $0.00 | semi annually | 2017-07-20 |
2017-06-28 | $0.00 | semi annually | 2017-07-13 |
2016-12-05 | $0.00 | semi annually | |
2016-09-12 | $0.00 | semi annually | |
2016-06-28 | $0.00 | semi annually | |
2016-06-17 | $0.00 | semi annually | |
2015-12-03 | $0.00 | semi annually | |
2015-09-10 | $0.00 | semi annually | |
2015-06-19 | $0.00 | semi annually | |
2015-06-09 | $0.00 | semi annually | |
2014-12-02 | $0.00 | semi annually | |
2014-09-11 | $0.00 | semi annually | |
2014-06-19 | $0.00 | semi annually | |
2014-06-05 | $0.00 | semi annually | |
2013-12-02 | $0.00 | semi annually |
Sino Biopharmaceutical Dividend per year
Sino Biopharmaceutical Dividend growth
Sino Biopharmaceutical Dividend Yield
Sino Biopharmaceutical current trailing twelve-month (TTM) dividend yield is 2.68%. Interested in purchasing Sino Biopharmaceutical stock? Use our calculator to estimate your expected dividend yield:
Sino Biopharmaceutical Financial Ratios
Sino Biopharmaceutical Dividend FAQ
Other factors to consider when evaluating Sino Biopharmaceutical as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Sino Biopharmaceutical stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Sino Biopharmaceutical's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Sino Biopharmaceutical publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Sino Biopharmaceutical distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Sino Biopharmaceutical are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Sino Biopharmaceutical sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Sino Biopharmaceutical distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Sino Biopharmaceutical declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Sino Biopharmaceutical's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Sino Biopharmaceutical's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.